文献速递肝病

781例儿童原发性硬化性胆管炎的自然史:一项多中心国际协作研究

The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.
PubMed 文献 · Hepatology · 2017-06-26

该多中心回顾性研究纳入36家机构781例儿童原发性硬化性胆管炎(PSC)患者,中位年龄12岁,随访4277人年。10年时38%和25%分别发生门静脉高压和胆道并发症,无事件生存率5年为70%、10年为53%。诊断时胆红素、γ-谷氨酰转移酶和天冬氨酸氨基转移酶-血小板比率指数升高者预后最差,PSC-炎症性肠病和小胆管型预后较好。

要点

  • 儿童PSC呈慢性进展性病程,10年时近半数患者出现不良肝脏结局
  • 诊断时胆红素、γ-谷氨酰转移酶和天冬氨酸氨基转移酶-血小板比率指数升高可识别最高风险患者
  • 小胆管型PSC和PSC-炎症性肠病是更有利的疾病表型

核心结论

  • 儿童PSC呈慢性进展性病程,10年病程后近半数患者出现不良肝脏结局。
  • 诊断时胆红素、γ-谷氨酰转移酶和天冬氨酸氨基转移酶-血小板比率指数升高可识别最高风险患者。
  • 小胆管型PSC和PSC-炎症性肠病是更有利的疾病表型。

研究设计与样本

  • 回顾性收集36家参与机构的全部儿童PSC病例,共781例,中位年龄12岁,随访4277人年。
  • 从PSC诊断日期至门静脉高压或胆道并发症、胆管癌、肝移植或死亡日期进行生存分析。
  • 按疾病表型和诊断时实验室检查分组分析,以识别长期结局的客观预测因素。

主要发现

  • 33%合并自身免疫性肝炎,76%合并炎症性肠病,13%为小胆管型PSC。
  • 病程10年时门静脉高压和胆道并发症分别发生于38%和25%的患者。
  • 发生门静脉高压或胆道并发症后,自体肝中位生存期分别为2.8年和3.5年。
  • 胆管癌发生率为1%。
  • 无事件生存率5年为70%、10年为53%。

关键数值与推荐

  • 诊断时总胆红素、γ-谷氨酰转移酶和天冬氨酸氨基转移酶-血小板比率指数升高最显著的患者组结局最差。
  • PSC-炎症性肠病风险比0.6(95%置信区间0.5-0.9),小胆管表型风险比0.7(95%置信区间0.5-0.96),均与有利预后相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long-term outcome. We identified 781 patients, median age 12 years, with 4,277 person-years of follow-up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event-free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC-inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5-0.9, and 0.7, 95% confidence interval 0.5-0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long-term outcome. CONCLUSION: PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC-inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518-527).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Deneau MR, El-Matary W, Valentino PL, et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology. 2017. PMID: 28390159. doi:10.1002/hep.29204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。